Generic drugs makers in Romania strike back at Government pricing plan

Newsroom 14/10/2016 | 13:42

The Generic Drugs Producers Association from Romania (APMGR) asks for a public debate for the drugs prices policy, claiming that the government’s draft bill designed to lower generic drugs prices by 35 percent in the next 3 years will not stop the dissapearance of products from the market.  

APMGR says that the new project is just a revision of the old prices order and doesn’t improve in any sense the critical situation of the generic drugs, that remain discriminated by applying the same double references at the lowest price from 12 reference countries and at 65 percent of the innovative drug price.

The computation methodology changes only for a limited number of drugs, on the list of the Global Health Organization as essential drugs, cannot have a beneficial impact as time as they continue to be penalized by the negative effects of clawback tax, applied undifferentiated, both for generic drugs as well as for the innovative ones, says the APMGR.

Moreover, the APMGR adds that the changes in stages of the off-patent drugs price doesn’t ensure a competitive environment for the generic drugs taking into account that this gradual reduction of the price does not apply for them.

„Instead of a change in the approach of the drugs strategy, the new methodology isn’t but a revision of the old policy, whose failure has been proven by the drugs disappearance from the market,” said Laurentiu Mihai, the executive director of APMGR.

Georgiana Bendre

BR Magazine | Latest Issue

Download PDF: Business Review Magazine March (II) 2024 Issue

The March (II) 2024 issue of Business Review Magazine is now available in digital format, featuring the main cover story titled “BAT DBS Romania Hub: A Vibrant New Office For An Employee-Centric
Newsroom | 27/03/2024 | 17:32
Advertisement Advertisement
Close ×

We use cookies for keeping our website reliable and secure, personalising content and ads, providing social media features and to analyse how our website is used.

Accept & continue